HYBRID EVENT: You can participate in person at Paris, France or Virtually from your home or work.

3rd Edition of International Heart Congress

June 05-07,2025 | Hybrid Event

June 05 -07, 2025 | Rome, Italy
Heart Congress 2024

Metabolic dysfunction spilling over to the heart

 Ahdy W Helmy, Speaker at Heart Conferences
Indiana University School of Medicine, United States
Title : Metabolic dysfunction spilling over to the heart


Metabolic Dysfunction and Metabolic Syndrome birthed with visceral adiposity, and Insulin resistance has wide spread implications. From a bed of inflammation at the visceral adipose tissue core, RAAS activation and constricted vascular micro-perfusion. To hyperinsulinemia and volume expansion. Eventually, Insulin resistance at the brain level promoting compromised satiety, and yet a continuum of sympathetic stimulation at the brain level. Hypertension is an offspring of that, aggravated by a spiral of weight gain. Eventually, visceral adipocytes in defiance to insulin as resistance increases rebel with lipolysis, and showering the vascular endothelium, liver and myocardium with free fatty acids, toxic and arrhythmogenic. The background is already set with a longer QT interval triggered by Insulin resistance and hyperinsulinemia. The lipo-toxicity sets beta cells islets on fire, compromise their capacity and prediabetes or diabetes result. Livers are pushed to steatosis & MASLD. Endothelial cells to a dysfunctional status with No Nitric Oxide, i.e.No No. Eventually cardiac steatosis, Diastolic dysfunction, atherosclerosis and coronary endothelial compromise with first microcirculatory failure and HFpEF. Later in the course of the problem coronary atherosclerosis and HFrEF.Interventions to break the cycle can be critical in reversing this evil spiral. This explains why unexpectedly therapies directed at reversing insulin resistance, visceral adiposity reduced MACE, cardiac death, and all cause mortality. Something we did not encounter with sulphonyl - urea drugs nor insulin therapy apart from saving lives preventing ketoacidosis in insulin deficiency but not in insulin resistance which is much bigger problem and a wide spread pandemic. Supportive Cardiovascular outcomes from GLP1RA, SGLT2 inhibitors, SGLT1/T2 inhibitors, GLP1RA/GIP RA, and the future Dutides and Trutides.

Audience Take Away

  • Mechanisms of cardiac compromise in the midst of the metabolic dysfunctional entangle
  • How to use therapies that work synergistically to protect the cardiac performance while improving insulin resistance and reducing hyperinsulinemia
  • How to avoid seemingly useful single directed therapies that may seem to help one area while compromising another angle of the metabolic dysfunction, e.g. Thiazide diuretics.


Dr. Helmy graduated from Alexandria University School of Medicine, did his first residency in Internal Medicine. Earned his Master Degree then PhD. Moved to the USA, did another Internal Medicine Residency at Indiana University, then a fellowship in Endocrinology & Metabolism at Indiana University. Became board certified in Internal Medicine, then Endocrinology, and had his 3rd board in Clinical Lipidology. Championed the establishment of the first advanced lipid testing and lipid clinic at The VA Medical Center at Indianapolis which is a part of Indiana University Medical center. He is an author, a clinician and a prolific teacher who earned numerous teaching award. A national and international speaker in multiple endocrinology topics mostly lipids, Metabolic Syndrome, Diabetes, and testosterone replacement.